Ten years on from their approval, GlobalData reviews their market entry strategies, pricing dynamics over time, and ...

It is the first of a slew of cancer drugs to now funded by Pharmac following the agency's multi-million dollar budget boost.

We recently published a list of 10 Best Major Stocks to Invest In According to Analysts. In this article, we are going to ...

And 1 October means families can claim the new childcare payment FamilyBoost that we announced in the Budget. This gives eligible parents a refund of 25 per cent of the Early Childhood Education (ECE) ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure.

The Japanese MHLW has granted approval for MSD’s KEYTRUDA (pembrolizumab) for lung and urothelial cancer indications.

This week on Pipeline Moves, the Clinical Trials Arena team investigates candidates in oncology, central nervous system and ...

Merck follows in the footsteps of Bristol Myers Squibb, which in December 2023 also failed to secure a late-stage victory for ...

After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...

Merck (MRK) stock is in focus as a Phase 3 trial for its cancer drug Keytruda in colorectal cancer patients did not meet ...

Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of ...